

Xiaoxing Feng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11428014/publications.pdf>

Version: 2024-02-01

16
papers

533
citations

687363

13
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

666
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, 1778-1785.	1.6	96
2	A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. <i>Cancer</i> , 2017, 123, 4556-4565.	4.1	61
3	Roles of Poly(ADP-Ribose) Glycohydrolase in DNA Damage and Apoptosis. <i>International Review of Cell and Molecular Biology</i> , 2013, 304, 227-281.	3.2	52
4	A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 2708-2716.	7.0	49
5	Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast adenocarcinoma cells. <i>International Journal of Oncology</i> , 2015, 46, 2267-2276.	3.3	44
6	A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 429-440.	2.3	35
7	Activation of Cell Death Mediated by Apoptosis-Inducing Factor Due to the Absence of Poly(ADP-ribose) Glycohydrolase. <i>Biochemistry</i> , 2011, 50, 2850-2859.	2.5	34
8	Enhanced cytotoxicity in triple-negative and estrogen receptor-positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel. <i>Oncology Reports</i> , 2015, 34, 1589-1598.	2.6	33
9	Enhanced DNA Accessibility and Increased DNA Damage Induced by the Absence of Poly(ADP-ribose) Hydrolysis. <i>Biochemistry</i> , 2010, 49, 7360-7366.	2.5	27
10	Silencing of Apoptosis-Inducing factor and poly(ADP-ribose) glycohydrolase reveals novel roles in breast cancer cell death after chemotherapy. <i>Molecular Cancer</i> , 2012, 11, 48.	19.2	20
11	Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. <i>Oncotarget</i> , 2021, 10, 1943253.	4.6	20
12	Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP-ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells. <i>International Journal of Oncology</i> , 2013, 42, 749-756.	3.3	14
13	Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 2946-2955.	2.8	14
14	Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100093.	1.1	14
15	Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6642-6652.	2.8	11
16	A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 461-470.	3.3	9